Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Early Versus Delayed Closure of Bladder Exstrophy in Female Patients

28 augusti 2026 uppdaterad av: Sajjad Ali, Khyber Teaching Hospital

Primary Single-Stage Early Versus Delayed Closure of Bladder Exstrophy in Female Patients: A Randomized Controlled Trial

This study compared two timings for primary single-stage surgery in female newborns with classic bladder exstrophy. Participants were randomly assigned to surgery within 72 hours of birth or at 6 to 12 weeks of age. Both groups received the same surgical repair and standardized perioperative care. The main outcome was successful closure of the bladder and abdominal wall 30 days after surgery. The study also evaluated wound dehiscence, surgical-site infection, urinary fistula, blood transfusion, reoperation, readmission, hospital stay, and adverse events.

Studieöversikt

Detaljerad beskrivning

Eligible phenotypic female neonates who presented with classic bladder exstrophy within the first 48 hours of life and met the prespecified clinical and anaesthetic criteria were enrolled through consecutive sampling. After written consent and baseline assessment, participants were randomized in a 1:1 ratio using a computer-generated sequence with randomly varying block sizes and stratification by centre. Allocation was implemented through sequentially numbered sealed envelopes prepared independently of recruitment.

Participants assigned to early closure underwent primary single-stage repair within 72 hours of birth. Participants assigned to delayed closure underwent the same repair at 6 to 12 weeks of age. Before delayed surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, while hydration and weight gain were monitored. The operation included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension. Perioperative care was standardized in both groups.

Participants were assessed on postoperative days 7, 14, and 30. Successful bladder closure on postoperative day 30 required an intact deep bladder and abdominal-wall closure without full-thickness wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion. Secondary outcomes were wound dehiscence, surgical-site infection, urinary fistula, blood transfusion, reoperation, readmission, hospital stay, and adverse events. The primary analysis followed the intention-to-treat principle.

Studietyp

Interventionell

Inskrivning (Faktisk)

124

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Khyber Pakhtunkhwa
      • Peshawar, Khyber Pakhtunkhwa, Pakistan
        • Khyber Teaching Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Phenotypic female neonates presenting with classic bladder exstrophy within the first 48 hours of life
  • Met the protocol-defined minimum birth-weight requirement
  • Gestational age of at least 34 weeks
  • Clinically stable and fit for general anaesthesia
  • Written informed consent provided by a parent or legal guardian

Exclusion Criteria:

  • Cloacal exstrophy, an exstrophy variant, or isolated epispadias
  • Previous bladder or abdominal-wall surgery
  • Life-threatening congenital anomaly
  • Uncontrolled sepsis
  • Coagulopathy
  • Cardiorespiratory instability precluding surgery within the assigned window
  • Parent or legal guardian unable or unwilling to comply with follow-up

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Early Closure
Participants underwent primary single-stage closure within 72 hours of birth.
Primary single-stage closure performed within 72 hours of birth. The procedure included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia during one anaesthetic. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
Aktiv komparator: Delayed Closure
Participants underwent primary single-stage closure at 6 to 12 weeks of age.
Primary single-stage closure performed at 6 to 12 weeks of age using the same operative checklist and repair. Before surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, with monitoring of hydration and weight gain. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Successful Bladder Closure at Postoperative Day 30
Tidsram: Postoperative day 30
Number and percentage of participants with an intact deep bladder and abdominal-wall closure without full-thickness abdominal wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion on or before postoperative day 30.
Postoperative day 30

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Wound Dehiscence Within 30 Days
Tidsram: From surgery through postoperative day 30
Number and percentage of participants with partial or complete, superficial or deep disruption of the operative wound within 30 days after surgery.
From surgery through postoperative day 30
Surgical-Site Infection Within 30 Days
Tidsram: From surgery through postoperative day 30
Number and percentage of participants with inflammatory signs at the operative site, with or without purulent discharge or positive culture, requiring antibiotic or surgical treatment within 30 days after surgery.
From surgery through postoperative day 30
Urinary Fistula Within 30 Days
Tidsram: From surgery through postoperative day 30
Number and percentage of participants with continuous urinary leakage from the wound or another site after surgery, confirmed clinically or by imaging and requiring continued drainage or intervention.
From surgery through postoperative day 30
Blood Transfusion
Tidsram: From the start of surgery through hospital discharge, up to 30 days after surgery
Number and percentage of participants who received a blood transfusion during the operative or perioperative period.
From the start of surgery through hospital discharge, up to 30 days after surgery
Reoperation Within 30 Days
Tidsram: From surgery through postoperative day 30
Number and percentage of participants who underwent a repeat surgical procedure related to the primary closure within 30 days after surgery.
From surgery through postoperative day 30
Readmission Within 30 Days
Tidsram: From discharge through postoperative day 30
Number and percentage of participants readmitted to hospital within 30 days after surgery.
From discharge through postoperative day 30
Hospital Stay
Tidsram: From surgery to hospital discharge, up to 30 days after surgery
Duration of the index postoperative hospital stay, measured in days from surgery to discharge.
From surgery to hospital discharge, up to 30 days after surgery
Any Adverse Event Within 30 Days
Tidsram: From surgery through postoperative day 30
Number and percentage of participants with at least one recorded adverse event within 30 days after surgery.
From surgery through postoperative day 30

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

28 januari 2021

Primärt slutförande (Faktisk)

15 mars 2026

Avslutad studie (Faktisk)

15 mars 2026

Studieregistreringsdatum

Först inskickad

24 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

28 augusti 2026

Första postat (Faktisk)

31 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

31 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera